Haemonetics Corp HAE
We take great care to ensure that the data presented and summarized in this overview for HAEMONETICS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HAE
View all-
Capital Research Global Investors Los Angeles, CA6.92MShares$506 Million0.13% of portfolio
-
Black Rock Inc. New York, NY5.96MShares$436 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.14MShares$376 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$281 Million0.06% of portfolio
-
Neuberger Berman Group LLC New York, NY3.83MShares$280 Million0.27% of portfolio
-
State Street Corp Boston, MA1.85MShares$135 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.64MShares$120 Million0.09% of portfolio
-
Franklin Resources Inc San Mateo, CA1.42MShares$104 Million0.04% of portfolio
-
Royce & Associates LP1.18MShares$86.2 Million0.95% of portfolio
-
Geode Capital Management, LLC Boston, MA1.17MShares$85.7 Million0.01% of portfolio
Latest Institutional Activity in HAE
Top Purchases
Top Sells
About HAE
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Insider Transactions at HAE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 17
2024
|
Laurie A. Miller SVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-1.32%
|
$18,088
$76.54 P/Share
|
Aug 29
2024
|
Simon, Christopher President & CEO |
SELL
Other acquisition or disposition
|
Direct |
39,704
-10.95%
|
$2,977,800
$75.56 P/Share
|
Jul 26
2024
|
Stewart W Strong President, Global Hospital |
SELL
Open market or private sale
|
Direct |
4,312
-19.16%
|
$392,392
$91.15 P/Share
|
Jul 25
2024
|
Stewart W Strong President, Global Hospital |
SELL
Payment of exercise price or tax liability
|
Direct |
2,798
-11.06%
|
$251,820
$90.58 P/Share
|
Jul 25
2024
|
Diane M Bryant Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+33.24%
|
-
|
Jul 25
2024
|
Robert E Abernathy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+9.01%
|
-
|
Jul 25
2024
|
Mark W Kroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+9.65%
|
-
|
Jul 25
2024
|
Lloyd Emerson Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+17.73%
|
-
|
Jul 25
2024
|
Charles J Dockendorff Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+33.24%
|
-
|
Jul 25
2024
|
Michael J Coyle Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+14.8%
|
-
|
Jul 25
2024
|
Ellen M Zane Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+11.69%
|
-
|
Jul 25
2024
|
Claire Pomeroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,207
+13.47%
|
-
|
Jul 24
2024
|
Stewart W Strong President, Global Hospital |
BUY
Grant, award, or other acquisition
|
Direct |
7,110
+21.93%
|
-
|
Jul 12
2024
|
Anila Lingamneni EVP, Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
79
-0.37%
|
$7,110
$90.0 P/Share
|
Jul 11
2024
|
Anila Lingamneni EVP, Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,136
-9.07%
|
$192,240
$90.0 P/Share
|
Jun 06
2024
|
Simon, Christopher President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
71,335
-16.44%
|
$6,206,145
$87.38 P/Share
|
Jun 06
2024
|
Simon, Christopher President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,516
+19.41%
|
$4,285,156
$41.64 P/Share
|
May 29
2024
|
Michelle L Basil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
12,990
-15.84%
|
$1,143,120
$88.22 P/Share
|
May 29
2024
|
Stewart W Strong President, Global Hospital |
SELL
Open market or private sale
|
Direct |
8,857
-32.74%
|
$770,559
$87.53 P/Share
|
May 28
2024
|
Anila Lingamneni EVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,279
-18.31%
|
$501,505
$95.73 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 241K shares |
---|---|
Exercise of conversion of derivative security | 109K shares |
Payment of exercise price or tax liability | 160K shares |
---|---|
Open market or private sale | 38.3K shares |
Bona fide gift | 38.9K shares |
Other acquisition or disposition | 39.7K shares |